Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,500 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph P. Lyssikatos sold 12,500 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $21.40, for a total transaction of $267,500.00. Following the transaction, the insider now owns 965,188 shares in the company, valued at $20,655,023.20. This represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Enliven Therapeutics Trading Up 4.3%

NASDAQ:ELVN traded up $0.87 during trading hours on Tuesday, reaching $21.16. 645,327 shares of the company's stock were exchanged, compared to its average volume of 293,740. The business's 50-day simple moving average is $18.94 and its two-hundred day simple moving average is $20.49. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). On average, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on ELVN shares. The Goldman Sachs Group started coverage on shares of Enliven Therapeutics in a research note on Monday, June 16th. They set a "buy" rating and a $37.00 price objective on the stock. Robert W. Baird raised their price objective on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, June 16th. HC Wainwright raised their target price on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. Finally, Jones Trading reduced their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a report on Friday, May 16th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $39.60.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Polar Capital Holdings Plc boosted its stake in shares of Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock valued at $53,768,000 after buying an additional 1,739,668 shares during the period. Boxer Capital Management LLC acquired a new stake in shares of Enliven Therapeutics during the 4th quarter valued at $15,106,000. Janus Henderson Group PLC raised its holdings in shares of Enliven Therapeutics by 27.9% during the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock valued at $30,001,000 after purchasing an additional 290,153 shares in the last quarter. FMR LLC raised its holdings in shares of Enliven Therapeutics by 3.2% during the 4th quarter. FMR LLC now owns 6,495,871 shares of the company's stock valued at $146,157,000 after purchasing an additional 199,692 shares in the last quarter. Finally, Pictet Asset Management Holding SA raised its holdings in shares of Enliven Therapeutics by 16.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock valued at $21,877,000 after purchasing an additional 135,969 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.